Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 45,078 shares at $52.35 ($2.3M) on 2022-02-24, disclosed to the SEC on 2022-02-25.
Open-market sale of $2.3M ITCI by Chairman, President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.92 | 100 | $5K | 0.2% |
| 2 | $51.61 | 11,240 | $580K | 24.8% |
| 3 | $51.61 | 11,240 | $580K | 24.8% |
| 4 | $52.35 | 11,249 | $589K | 25.1% |
| 5 | $52.35 | 11,249 | $589K | 25.1% |
| Total | $51.98 avg | 45,078 |
| $2.3M |
| 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |